Assignee
C4 THERAPEUTICS INC
US·36 granted patents·26 pending applications·243 citations·filing 2018–2025
Top patents by PatentIndex Score
62 records- 0197US11584748B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Feb 21, 2023·11 cites·11 claims
- 0297US11407732B1Tricyclic degraders of Ikaros and AiolosC4 THERAPEUTICS INC·Filed 2021·Granted Aug 9, 2022·10 cites·30 claims
- 0397US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0497US10660968B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·32 cites·35 claims
- 0596US11623929B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2020·Granted Apr 11, 2023·7 cites·20 claims
- 0696US11524949B2Degraders and Degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Dec 13, 2022·7 cites·18 claims
- 0796US10905768B1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·31 cites·20 claims
- 0896US10849982B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted Dec 1, 2020·43 cites·17 claims
- 0996US10646575B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·32 cites·28 claims
- 1095US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 1195US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 1294US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 1394US11254672B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Feb 22, 2022·7 cites·22 claims
- 1493US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 1593US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1693US11802131B2Glutarimides for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Oct 31, 2023·4 cites·9 claims
- 1793US11787802B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·3 cites·19 claims
- 1893US11691972B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2021·Granted Jul 4, 2023·5 cites·10 claims
- 1992US11401256B2Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·5 cites·26 claims
- 2090US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 2190US2026042782A1Isoindolinone and indazole compounds for the degradation of egfrC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2289US12157735B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Dec 3, 2024·1 cites·23 claims
- 2388US12049464B2Compounds for targeted degradation of BRD9C4 THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·11 claims
- 2487US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 2587US12091397B2Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·1 cites·13 claims
- 2685US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 2783US2026015362A1N/o-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2883US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2983US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3081US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 3181US11753397B2Cereblon binders for the degradation of ikarosC4 THERAPEUTICS INC·Filed 2020·Granted Sep 12, 2023·1 cites·19 claims
- 3281US2025084081A1Compounds for targeted degradation of brd9C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3380US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 3480US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3579US12421220B2Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·26 claims
- 3679US12365681B2Dihydrobenzimidazolones for medical treatmentC4 THERAPEUTICS INC·Filed 2023·Granted Jul 22, 2025·0 cites·16 claims
- 3779US12227504B2Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Granted Feb 18, 2025·0 cites·13 claims
- 3879US2025382285A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3979US2025368631A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4077US2025084055A1Dihydroquinolinones for medical treatmentC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4176US12441740B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
- 4273US2026015338A1Targeted protein degradationC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4371US2024018156A1Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4470US12570626B2Degraders and degrons for targeted protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Mar 10, 2026·0 cites·16 claims
- 4570US2025282780A1Spirocyclic compoundsC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4670US2024199581A1Therapeutics for the degradation of mutant brafC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4769US2024199638A1Glutarimides for medical treatmentC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4867US2023082430A1Tricyclic degraders of ikaros and aiolosC4 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4963US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 5063US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when C4 THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →